Sanofi India Q4 FY26 Results PAT Growth as Prescription Pharma Portfolio Delivers

Wed Apr 29 2026

Sanofi India Q4 FY26 financial results are announced on April 28, 2026, posting a PAT of Rs 92 crore higher year-on-year, as the Pharmaceuticals company delivered its January to March 2026 quarter earnings. Investors seeking live stock data, expert analysis, and research on Sanofi India Q4 FY26 results can track the stock at Sanofi India on Univest.

Table of Contents

Sanofi India Q4 FY26 Financial Highlights

Sanofi India Limited Q4 FY26 financial results are out on April 28, 2026. The listed subsidiary of global pharma major Sanofi SA reported improved profitability driven by its prescription pharmaceutical portfolio including diabetes, cardiovascular, and specialty medicines.

Metric	Q4 FY26	Q4 FY25	Change
Revenue / Total Income	approximately Rs 720 crore	Refer NSE filing	Grew (year-on-year growth)
PAT	Rs 92 crore	Refer NSE filing	Higher YoY
Full Year FY26 PAT	Refer annual filing	Refer filing	As reported
Dividend	Not declared	Refer filing	FY26 final

Sanofi India Q4 FY26 Performance Analysis

Sanofi India’s prescription portfolio, including Lantus (insulin glargine) and cardiovascular brands, continued to generate steady revenue in Q4 FY26, benefiting from chronic disease management growth across India’s urban and semi-urban markets.

The company’s operational efficiency and cost management focus contributed to margin improvement in Q4 FY26. Sanofi India has been a consistent dividend-paying company and maintains high standards of corporate governance as a multinational subsidiary.

Also Read: Bhansali Engineering Polymers Q4 FY26 Results

Full Year FY26 Business Summary

Management Outlook and FY27 Priorities

Sanofi India Q4 FY27 growth will be driven by expanding access to its diabetes and specialty care portfolio. The global parent’s pipeline of specialty biologics, if approved for India, could significantly expand the India business in the medium term.

Conclusion

Sanofi India Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter with PAT of Rs 92 crore. The Pharmaceuticals company’s results are an important input for investors tracking the earnings season. Investors should review the full exchange filing on NSE and BSE for complete audited financials before making any investment decisions.

This article is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decisions. Past performance is not indicative of future results.

Get free investment predictions on Univest.

Frequently Asked Questions FAQs

What was Sanofi India Q4 FY26 PAT?

Sanofi India Q4 FY26 records PAT of Rs 92 crore, higher year-on-year. The results were announced on April 28, 2026 via exchange filings on NSE and BSE.

What was Sanofi India revenue in Q4 FY26?

Sanofi India Q4 FY26 records revenue of approximately Rs 720 crore (year-on-year growth). Investors should refer to the complete NSE and BSE exchange filing for the audited revenue breakdown.

Did Sanofi India declare a dividend for FY26?

As per available information, Sanofi India has not declared a dividend for FY26 in the Q4 results announcement. Refer to the official exchange filing for the latest update.

How did Sanofi India perform in FY26 overall?

FY26 was a year of stable growth for Sanofi India, with the prescription pharma business benefiting from increasing diabetes and cardiovascular disease burden in India and growing physician and patient engagement programmes…. Investors can track the complete annual performance metrics in the company’s FY26 annual report and exchange filings.

What is the outlook for Sanofi India in FY27?

Sanofi India FY27 growth will be driven by expanding access to its diabetes and specialty care portfolio. The global parent’s pipeline of specialty biologics, if approved for India, could significantly expand the India business in the medium term.. For real-time updates on the stock, investors should monitor regulatory filings and analyst commentary.

Where can I track Sanofi India stock and results?

Investors can track Sanofi India (NSE: SANOFI) share price, financial results, and analyst data on NSE India, BSE India, and financial platforms. The Q4 FY26 results were filed on April 28, 2026.

What sector does Sanofi India operate in?

Sanofi India operates in the Pharmaceuticals sector in India. The company is listed on both NSE and BSE. Investors should review the company’s business model, competitive positioning, and risk factors before making any investment decision.

Is Sanofi India a good investment after Q4 FY26 results?

Whether Sanofi India is a good investment depends on your individual financial goals, risk tolerance, and investment horizon. The Q4 FY26 results provide one data point about the company’s performance. Please consult a SEBI registered financial advisor before making any investment decision.